IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Insight Molecular Diagnostics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.89−0.12 (-3.99%)
Close on Oct 19, 2026
- Market cap
- $106.21M
- P/E (TTM)
- –
- Dividend yield
- –
Insight Molecular Diagnostics Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Laboratory Services [Member] | $1.65M | $1.93M | $4.03M | $4.38M | $4.23M | $3.84M | $1.86M | 98.7% | -61.0% |
| Kitted Products [Member] | $21.00K | $24.00K | $24.00K | $24.00K | $24.00K | $0 | $0 | 1.3% | -12.5% |
| Laboratory Developed Test Services [Member] | – | – | $0 | $0 | $0 | $0 | $22.00K | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| United States | $1.65M | $1.93M | $4.03M | $4.36M | $4.22M | $3.79M | $1.67M | 98.7% | -60.9% |
| United Kingdom | – | – | $0 | $0 | $0 | $0 | $45.00K | – | – |
| Europe [Member] | – | – | $24.00K | – | – | – | $18.00K | – | – |
| Asia Pacific [Member] | – | – | $0 | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Insight Molecular Diagnostics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.